{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Celecoxib+400+mg", "query": { "intervention": "Celecoxib 400 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 74, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Celecoxib+400+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-17T17:35:44.020Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00504660", "title": "6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Glioma of Brain", "Glioblastoma Multiforme", "Brain Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Celecoxib (Celebrex)", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "6-Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 75, "start_date": "2003-09", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2012-01-11", "last_synced_at": "2026-09-17T17:35:44.020Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00504660" }, { "nct_id": "NCT01313429", "title": "Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Melanoma", "Epithelial Malignancies", "Pleural Malignancies" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Allogenic tumor Cell Vaccine (K562)", "type": "BIOLOGICAL" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 19, "start_date": "2011-03-04", "completion_date": "2020-02-26", "has_results": false, "last_update_posted_date": "2020-03-03", "last_synced_at": "2026-09-17T17:35:44.020Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313429" }, { "nct_id": "NCT00400374", "title": "Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2007-08", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2018-03-15", "last_synced_at": "2026-09-17T17:35:44.020Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00400374" }, { "nct_id": "NCT00061906", "title": "Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2003-01", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2014-02-11", "last_synced_at": "2026-09-17T17:35:44.020Z", "location_count": 2, "location_summary": "Columbus, Ohio • Houston, Texas", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061906" }, { "nct_id": "NCT01849055", "title": "A Multiple Dose Study of LY3023703 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "LY3023703", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 48, "start_date": "2013-05", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2018-12-14", "last_synced_at": "2026-09-17T17:35:44.020Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01849055" }, { "nct_id": "NCT00223691", "title": "Treatment of Orthostatic Hypotension in Autonomic Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autonomic Failure", "Orthostatic Hypotension" ], "interventions": [ { "name": "Atomoxetine", "type": "DRUG" }, { "name": "Acarbose", "type": "DRUG" }, { "name": "Pyridostigmine Bromide", "type": "DRUG" }, { "name": "Yohimbine", "type": "DRUG" }, { "name": "Midodrine HCl", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Modafinil", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "water intake", "type": "OTHER" }, { "name": "Diphenhydramine Hydrochloride", "type": "DRUG" }, { "name": "Ranitidine HCL", "type": "DRUG" }, { "name": "Tranylcypromine", "type": "DRUG" }, { "name": "Ergotamine/ Caffeine", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Pseudoephedrine", "type": "DRUG" }, { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Oxymetazoline 0.05% nasal solution", "type": "DRUG" }, { "name": "Bovril", "type": "DIETARY_SUPPLEMENT" }, { "name": "Acetazolamide", "type": "DRUG" }, { "name": "Rivastigmine tartrate", "type": "DRUG" }, { "name": "Carbidopa/levodopa", "type": "DRUG" }, { "name": "Inflatable abdominal binder", "type": "DEVICE" }, { "name": "inflatable abdominal binder (sham)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT", "DEVICE" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 389, "start_date": "2002-03", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-01-18", "last_synced_at": "2026-09-17T17:35:44.020Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00223691" }, { "nct_id": "NCT03912428", "title": "Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myositis", "Inflammatory", "Rheumatoid Arthritis", "Healthy Volunteers" ], "interventions": [ { "name": "11C-MC1", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "[11C]ER176", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET)/computed tomography (CT) Scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 31, "start_date": "2019-06-14", "completion_date": "2024-06-14", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-09-17T17:35:44.020Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03912428" }, { "nct_id": "NCT01129245", "title": "The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovulation", "Luteal Development" ], "interventions": [ { "name": "Celebrex", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "FEMALE", "summary": "18 Years to 35 Years · Female only" }, "enrollment_count": 20, "start_date": "2009-09", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2019-06-18", "last_synced_at": "2026-09-17T17:35:44.020Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01129245" }, { "nct_id": "NCT02840162", "title": "Pre-Prostatectomy Celecoxib or Placebo", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Prostate Cancer" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 34, "start_date": "2001-05", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-09-17T17:35:44.020Z", "location_count": 2, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02840162" }, { "nct_id": "NCT01341496", "title": "Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Melanoma", "Epithelial Malignancies", "Pleural Malignancy" ], "interventions": [ { "name": "Epigenetically Modified Autologous Tumor", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 41, "start_date": "2011-04-18", "completion_date": "2016-07-21", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-09-17T17:35:44.020Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01341496" } ] }